HLS Therapeutics Inc.
HLS Therapeutics Inc. (HLS.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
HLS.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsHLS Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.06B, a decrease of 0.26% year-over-year from $0.06B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.06B | -$0.00B | -0.26% |
| 2024-12-31 | $0.06B | -$0.01B | -10.23% |
| 2023-12-31 | $0.06B | +$0.00B | +2.61% |
| 2022-12-31 | $0.06B | +$0.00B | +2.43% |
| 2021-12-31 | $0.06B | +$0.00B | +6.95% |
| 2020-12-31 | $0.06B | +$0.00B | +3.60% |
| 2019-12-31 | $0.05B | -$0.01B | -11.81% |
| 2018-12-31 | $0.06B | -$0.01B | -18.20% |
| 2017-12-31 | $0.08B | +$0.02B | +38.96% |
| 2016-12-31 | $0.05B | +$0.03B | +170.75% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income HLS Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
HLS Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from HLS Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
HLS.TO revenue · 4 questionsHLS.TO's trailing twelve-month (TTM) revenue is $0.06B. That is a decrease of 0.26% year-over-year from $0.06B in FY2025.
▸ Source: FMP · HLS Therapeutics Inc. SEC filings · GAAP · HLS Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026